Joakim Nordanstig: SWEDEPAD Data Show Early Risk Of Limb Loss With Paclitaxel-Coated Devices
Joakim Nordanstig, President at Swedish Society for Vascular Surgery (SSVS), shared a post on LinkedIn:
”Very honoured to have been invited to the absolutely amazing Charing Cross Vascular and Endovascular Consensus Meeting in London this week.
Today, we provided data updates from the SWEDEPAD trials, including a detailed subgroup analysis in Rutherford 5-6 patients from SWEDEPAD 1, demonstrating an increased early risk for limb loss in patients treated with paclitaxel-coated devices compared to uncoated devices.
This observation may explain to overall neutral results in terms of major amputation rates (the primary endpoint) previously reported from SWEDEPAD 1. My colleague (dr Mårten Falkenberg) also presented important cause-specific mortality rate data from both SWEDEPAD 1 and 2 in an effort to better understand the late mortality signal noted with paclitaxel-coated devices.
We also presented vessel segment-specific data, showing that the previously reported reduced TVR rates with paclitaxel-coated devices was mainly driven by interventions in the femoropopliteal segment, whereas results were neutral infrapopliteally.”
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care